In addition, recent reports found a lower risk of POAG with glucagon‐like peptide‐1 receptor (GLP‐1R) agonists [13, 14], while another study suggests that T2D patients treated with sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have a reduced risk of incident glaucoma, compared to GLP‐1R agonists [15]. This evidence concerns the gene GLP1R and glaucoma.